Search
forLearn
5 / 801 resultslearn RH410
learn KX-826
learn TDM-105795
learn GT20029
research compound made to degrade androgen receptors in scalp
Research
5 / 1000+ resultsresearch Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss, with fewer side effects than oral finasteride.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.
research Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
CG2001 is safe and well-tolerated for treating hair loss in men.
research The Pathogenesis of Primary Cicatricial Alopecias
The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.
research Diet in dermatology: Revisited
Certain diets can affect skin conditions, but more research is needed to understand these relationships fully.
Community Join
5 / 1000+ resultscommunity Any updates or news on Gt20029?
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
community When will gt20029 come out???
The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.
community Where are we with GT20029 ? Realistic Timeline ?
GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
community GT20029 Phase 2 results are out
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.